Top 3 Australian AI Healthcare Stocks To Watch In September 2026

Global government bond yields are edging toward 4%, which raises borrowing costs and pressures many growth stories that rely on cheap capital. That backdrop pushes investors to look harder at Australian healthcare stocks using artificial intelligence, where the pitch is more about long-term problem solving than fast money. This article highlights three stocks from a specialist AI-in-healthcare screener that helps filter that crowded space.

The three stocks below are just a starter pack, and the full screen surfaced 5 more Australian healthcare AI companies with equally compelling stories that are not covered here. To go straight to the source and identify which ideas best fit your own portfolio filters, analyze the full Transformative Artificial intelligence (AI) Healthcare Stocks screener

Beamtree Holdings (ASX:BMT)

Overview: Beamtree Holdings provides AI driven clinical decision support, diagnostic monitoring and coding analytics software that helps hospitals make faster, safer, more accurate care decisions.

Operations: Beamtree generates about A$7.9 million from Diagnostics, A$12.2 million from Knowledge Networks and A$8.8 million from Coding & Data Quality, mainly in Australia.

Market Cap: A$30 million

Beamtree Holdings matters for this AI healthcare screener because its software tries to move hospitals toward data led, automated decisions rather than manual coding and ad hoc judgment. This is a key area where AI can influence both quality of care and cost structures.

"Rollout of fully hands off autonomous coding in Australia, the U.K. and Canada is set to convert pilot programs into scalable commercial contracts, increasing recurring software revenue and supporting earnings growth through high gross margins."

What happens to Beamtree’s margin profile if a single assumption about how quickly hospitals adopt that AI driven automation breaks?

If that adoption curve is the real swing factor, the full narrative for Beamtree Holdings explains how Beamtree Holdings could still accelerate or stall from this point.

ImExHS (ASX:IME)

Overview: ImExHS provides AI informed cloud medical imaging software and outsourced radiology services that support diagnostics across radiology, cardiology and pathology.

Operations: ImExHS generates about A$10 million from Software and A$21 million from Radiology, with roughly A$31 million earned in Latin America.

Market Cap: A$17 million

ImExHS matters for this Transformative AI Healthcare screener because its imaging platforms and teleradiology services feed real world scan data into AI tools that aim to sharpen diagnostics while supporting remote workflows.

"Management team seems to have done a good job across the board: cash, price, volume, renegotiations, cost control, efficiency, etc."

What happens to ImExHS if one big assumption about how quickly hospitals lean into those AI centric imaging workflows does not hold?

If that pacing risk is what matters most, read the full narrative for ImExHS to see how ImExHS could turn careful execution into accelerating scale and pricing power.

Artrya (ASX:AYA)

Overview: Artrya develops its Salix cloud platform, which uses artificial intelligence on coronary CT scans to detect and manage coronary artery disease risk.

Operations: Artrya currently reports about A$0.03 million from developing AI driven CCTA image analysis technology, all generated in Australia.

Market Cap: A$631 million

Artrya matters for this Transformative AI Healthcare screener because Salix aims to turn routine coronary CT imaging into a real time, algorithm guided triage tool for heart attack risk.

"Growing adoption of CCTA as a front-line tool for chest pain assessment, together with up to 400,000 scans a year across SAPPHIRE partners at a blended rate of about US$850 per scan across three modules, gives Artrya a clear volume pathway that directly targets future subscription and fee per scan revenue."

What happens to Artrya’s earnings profile if one quiet assumption about how quickly that scan volume translates into paid usage breaks?

If that revenue conversion is the quiet hinge, read the full narrative for Artrya to see how Artrya could turn scan volume into accelerating subscription firepower.

Seeking Fresh Alternatives Before They Fly

Fresh ideas move first, and the best breakouts often slip away while investors hesitate and prices keep running. Scan these curated shortlists before the crowd catches up and consider acting sooner rather than later.

• Spot stronger balance sheets before momentum investors arrive by running the list of solid balance sheet and fundamentals (12 results), which filters for sturdier cash positions and cleaner fundamentals while they are still under the radar for now.
• Explore early momentum in AI infrastructure suppliers using the curated 85 AI infrastructure stocks set, built to surface potential enablers of the data surge before prices move significantly.
• Track income ideas that aim to keep paying while others are dropping by scanning the hand picked 3 dividend fortresses, which focuses on higher yield opportunities before demand becomes elevated.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com